Welcome to our dedicated page for Ocugen SEC filings (Ticker: OCGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ocugen, Inc. filings document the regulatory record for a Nasdaq-listed biotechnology company developing modifier gene therapies for retinal diseases. Form 8-K disclosures cover clinical and Regulation FD updates for programs including OCU410, capital-structure events such as warrant exercises and 6.75% convertible senior notes due 2034, and material agreements tied to the note indenture and loan repayment.
Proxy materials describe annual meeting proposals, shareholder voting matters, and governance practices. Other filings identify the company's common stock on The Nasdaq Capital Market, preliminary financial information, authorized-share validation matters, and furnished investor presentations containing forward-looking clinical-development statements.
Ocugen, Inc. files a definitive proxy for its virtual Annual Meeting on June 11, 2026 and reviews 2025 progress across clinical, business development, financing, and governance fronts. The company completed enrollment in the Phase 3 liMeliGhT trial for OCU400 with 140 patients (2:1 randomized) and targets topline data in Q1 2027. OCU400 is positioned as a modifier gene therapy intended to address broad retinitis pigmentosa mutations; Ocugen executed a regional license for Korea with Kwangdong Pharmaceutical.
OCU410 reported Phase 2 results showing a 31% statistically significant reduction in lesion growth (optimal dose), 27% ellipsoid zone preservation, and 55% of treated patients with ≥30% lesion reduction. A planned pivotal Phase 3 cohort may enroll up to 300 subjects. The GARDian3 Phase 2/3 trial for OCU410ST enrolled 63 participants. Financing actions included a $22.5M registered direct offering in January 2026 and a $15M warrant exercise (10 million shares), which Ocugen says extends cash runway into Q1 2027. Leadership additions include a new CFO and senior commercial and operations hires. Proxy items include election of two Class III directors and a proposed reverse stock split in the range 1-for-4 to 1-for-8.
Ocugen, Inc. disclosed a Schedule 13G showing that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report shared voting and dispositive power over 17,074,584 shares of Common Stock (CUSIP 67577C105), representing 5.2% of the class. The filing is a joint filing and is signed April 13, 2026.
Ocugen, Inc. director Zhang Junge exercised stock options to acquire additional common shares. On April 1, 2026, he exercised options covering 194,134 shares of common stock at exercise prices of $0.51, $0.46, and $1.42 per share. Following these exercises, he directly owns 1,359,316 common shares. The options had previously vested and become exercisable between January 2020 and June 2025.
Ocugen Inc common stock ownership filing shows The Vanguard Group reports zero beneficial ownership and 0% of the class. The filing explains an internal realignment of Vanguard effective January 12, 1998 that led certain subsidiaries to report separately. The form is signed by Ashley Grim on 03/27/2026.
Ocugen, Inc. furnished an investor presentation outlining progress in its gene therapy pipeline for blinding retinal diseases. The company is targeting three biologics license applications over three years for retinitis pigmentosa, Stargardt disease, and geographic atrophy.
OCU400 for retinitis pigmentosa is in Phase 3 with enrollment completed; Phase 1/2 data showed durable visual function gains over three years and no related severe adverse events, with 88% of treated evaluable subjects showing improvement or preservation versus untreated eyes. OCU410ST for Stargardt disease has initiated a pivotal Phase 2/3 trial after Phase 1 data showed atrophic lesion growth 54% slower and visual function stabilized or improved in all treated eyes.
OCU410 for geographic atrophy delivered positive preliminary 12‑month Phase 2 results, including a 31% reduction in lesion size and 27% slower ellipsoid zone loss at the medium dose compared with controls, with no serious or special-interest adverse events deemed related to OCU410. Ocugen plans to start a global Phase 3 GA trial and progress rolling BLA submissions as key upcoming milestones.
Ocugen, Inc. reported positive 12‑month topline Phase 2 ArMaDa data for OCU410, its modifier gene therapy for geographic atrophy secondary to dry age‑related macular degeneration. The optimal medium dose showed a 31% reduction in GA lesion growth versus control at 12 months and a 27% slower loss of the ellipsoid zone, a structural marker linked to visual function. Across treated patients there were no OCU410‑related serious adverse events or adverse events of special interest, supporting a favorable safety and tolerability profile. Based on these results, Ocugen plans to initiate a global Phase 3 registrational trial of OCU410 with up to 300 subjects in the third quarter of 2026, as part of its broader goal of three biologics license applications in three years.
Ocugen, Inc. reports that an institutional investor partially exercised previously issued warrants and purchased 10,000,000 shares of common stock on March 12, 2026. This warrant exercise generated gross proceeds of $15.0 million for Ocugen. The company states that, based on this cash infusion, it now anticipates its cash runway will extend into the first quarter of 2027, supporting ongoing operations and development plans.
Ocugen, Inc. Chief Financial Officer Treerita Essalima Johnson-Greene filed an initial statement of beneficial ownership. The filing reports 750,000 options to buy Ocugen stock and 500,000 common shares held directly, plus 350 common shares held indirectly by a spouse.
The reported option vests in equal annual installments over three years beginning on February 17, 2027, subject to continued service with the company on each vesting date. This filing establishes the CFO’s starting equity position as a reporting insider.
Ocugen, Inc. is a late-stage biotechnology company focused on gene therapies and biologics for serious eye diseases, a regenerative knee cartilage implant, and an inhaled mucosal vaccine platform. Its lead modifier gene therapy, OCU400 for retinitis pigmentosa, has completed Phase 3 enrollment of 140 subjects, with a rolling BLA planned to begin in the third quarter of 2026 and topline data expected in the first quarter of 2027. Long-term Phase 1/2 data show approximately 2-line LLVA gains and durable safety across multiple mutations.
OCU410 and OCU410ST, both based on the RORA gene, target geographic atrophy and Stargardt disease, respectively. Phase 2 ArMaDa data for OCU410 showed a 46% reduction in lesion growth at 12 months versus control and a favorable safety profile, while Phase 1 GARDian1 data for OCU410ST showed atrophic lesion growth 54% slower at 12 months in treated eyes and 100% stabilization or improvement in visual function among evaluable treated eyes. A 51-patient Phase 2/3 pivotal trial for OCU410ST is underway, with enrollment expected to complete in early 2026 and a BLA submission planned in the first half of 2027.
The company is also developing OCU200, a fusion protein for DME, DR, and wet AMD now in a multicenter Phase 1 trial, and NeoCart, a Phase 3-ready autologous knee cartilage implant held in its OrthoCellix subsidiary. Its inhaled COVID-19 vaccine candidate OCU500 will enter a Phase 1 trial funded by NIAID’s Project NextGen, and Ocugen reports 80 patents and 66 pending applications worldwide supporting its pipeline and partnered programs.
Ocugen, Inc. has filed an 8-K describing a petition to the Delaware Court of Chancery under Section 205 of the Delaware General Corporation Law. The company asks the court to validate a charter amendment that increased authorized common shares from 295,000,000 to 390,000,000 and to confirm the validity of shares issued based on that change.
The petition follows a stockholder lawsuit challenging whether special Series C preferred stock could vote on the 2024 share increase proposal. Ocugen states it acted in good faith, that a correction filing fixed any drafting issue, and that about 33,009,874 shares have been issued in reliance on the amendment. A hearing on the petition is scheduled for May 6, 2026, and the stockholder plaintiff does not oppose the requested relief.